ClinConnect ClinConnect Logo
Search / Trial NCT06988605

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Launched by GALDERMA R&D · May 16, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called nemolizumab (brand name: Nemluvio®) for treating moderate-to-severe atopic dermatitis, a chronic skin condition that causes red, itchy patches. The goal is to see how well this treatment works in real-life situations over a period of six months, based on assessments by doctors and feedback from patients themselves.

To be eligible for this trial, participants must be adolescents or adults aged 12 and older who are starting treatment with nemolizumab as recommended by their doctor. They need to provide consent to join the study, either themselves or through a legal representative. However, people who cannot use nemolizumab for medical reasons, have received other experimental treatments in the last three months, or have previously used nemolizumab are not eligible to participate. Those who join the trial can expect regular check-ins to assess their progress and share their experiences with the treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
  • Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
  • Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
  • Exclusion Criteria:
  • Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
  • Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
  • Participants who received nemolizumab previously.
  • Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

About Galderma R&D

Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.

Locations

Buxtehude, , Germany

Castle Rock, Colorado, United States

Fairfield, Connecticut, United States

Cutler Bay, Florida, United States

Brighton, Massachusetts, United States

Lee's Summit, Missouri, United States

East Syracuse, New York, United States

Dallas, Texas, United States

Berlin, , Germany

Birmingham, Alabama, United States

Phoenix, Arizona, United States

Phoenix, Arizona, United States

Phoenix, Arizona, United States

Tucson, Arizona, United States

Corona, California, United States

Fountain Valley, California, United States

Fremont, California, United States

Irvine, California, United States

Los Angeles, California, United States

Newport Beach, California, United States

San Francisco, California, United States

Santa Monica, California, United States

Thousand Oaks, California, United States

Coral Gables, Florida, United States

Jupiter, Florida, United States

Miami, Florida, United States

Miami, Florida, United States

Miami, Florida, United States

North Miami Beach, Florida, United States

Saint Petersburg, Florida, United States

Tampa, Florida, United States

Tampa, Florida, United States

Chicago, Illinois, United States

Indianapolis, Indiana, United States

West Lafayette, Indiana, United States

Columbia, Maryland, United States

Glenn Dale, Maryland, United States

Rockville, Maryland, United States

Milford, Massachusetts, United States

Auburn Hills, Michigan, United States

Caledonia, Michigan, United States

Grandville, Michigan, United States

Troy, Michigan, United States

Saint Louis, Missouri, United States

Las Vegas, Nevada, United States

Portsmouth, New Hampshire, United States

Auburn, New York, United States

Mount Kisco, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Dayton, Ohio, United States

Gresham, Oregon, United States

Philadelphia, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Bluffton, South Carolina, United States

Cedar Park, Texas, United States

Edinburg, Texas, United States

Grapevine, Texas, United States

Houston, Texas, United States

Sugar Land, Texas, United States

Waco, Texas, United States

Bountiful, Utah, United States

Vienna, Virginia, United States

Karlsruhe, , Germany

Langenau, , Germany

Augsburg, Bayern, Germany

Erlangen, Bayern, Germany

Regensburg, Bayern, Germany

Remscheid, Nordrhein Westfalen, Germany

Ahaus, , Germany

Augsburg, , Germany

Berlin, , Germany

Berlin, , Germany

Bernau Bei Berlin, , Germany

Bielefeld, , Germany

Gladbeck, , Germany

Großenhain, , Germany

Haslach Im Kinzigtal, , Germany

Hersbruck, , Germany

Koblenz, , Germany

Lübeck, , Germany

Mainz, , Germany

Oberursel, , Germany

Oranienburg, , Germany

Pforzheim, , Germany

Quedlinburg, , Germany

London, Hampshire, United Kingdom

Southampton, Hampshire, United Kingdom

Watford, Hertfordshire, United Kingdom

King's Lynn, Norfolk, United Kingdom

Harrogate, North Yorkshire, United Kingdom

Sheffield, South Yorkshire, United Kingdom

London, Surrey, United Kingdom

Birmingham, West Midlands, United Kingdom

Leeds, West Yorkshire, United Kingdom

York, Yorkshire, United Kingdom

Bridgend, , United Kingdom

Epsom, , United Kingdom

Harrow, , United Kingdom

Kingston Upon Thames, , United Kingdom

Liverpool, , United Kingdom

London, , United Kingdom

London, , United Kingdom

Manchester, , United Kingdom

Redhill, , United Kingdom

Sandbach, , United Kingdom

Swansea, , United Kingdom

Wirral, , United Kingdom

Wolverhampton, , United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported